Company Performance - Adma Biologics (ADMA) closed at $16.07, down 0.62% from the previous trading session, underperforming the S&P 500's gain of 0.24% [1] - Over the past month, shares of Adma Biologics have gained 0.06%, lagging behind the Medical sector's gain of 3.63% and the S&P 500's gain of 2.37% [1] Financial Projections - The upcoming earnings per share (EPS) for Adma Biologics is projected to be $0.15, representing a 275% increase from the same quarter last year [2] - Revenue is estimated to be $112.2 million, reflecting a 51.83% increase from the prior-year quarter [2] Analyst Forecasts - Recent revisions to analyst forecasts for Adma Biologics are important as they indicate evolving short-term business trends, with positive revisions suggesting optimism about the company's outlook [3] - The Zacks Rank system, which incorporates estimate changes, aims to provide actionable ratings based on these revisions [4] Zacks Rank and Valuation - Adma Biologics currently holds a Zacks Rank of 3 (Hold), with the consensus EPS estimate moving 2.24% higher over the past month [5] - The company has a Forward P/E ratio of 23.61, which is a premium compared to the industry average Forward P/E of 22.58 [6] Industry Context - The Medical - Biomedical and Genetics industry, which includes Adma Biologics, holds a Zacks Industry Rank of 68, placing it in the top 28% of over 250 industries [6] - The Zacks Industry Rank measures the strength of industry groups based on the average Zacks Rank of individual stocks, indicating that top-rated industries outperform lower-rated ones by a factor of 2 to 1 [7]

Pharmaceutical concern ADMA Biologics Inc (NASDAQ:ADMA) has been consolidating above familiar pressure at the $16 region since mid-January. A breakout could be on the way, however, as the stock just came into contact with a historically bullish trendline. Per Schaeffer's Senior Quantitative Analyst Rocky White, ADMA has come within striking distance of its 200-day moving average after a lengthy period above it (defined by White as 80% of the time over the past two months and 8 of the last 10 trading days). ...

ADMA Biologics’ (ADMA) shares have lost 8.9% in a month against the industry’s growth of 6.6%.The company has put up a phenomenal performance in 2024 and hit a 52-week high of $23.64 on Nov. 11.Last month, ADMA reported preliminary revenues for 2024 and provided a business update. On a preliminary basis, total revenues in 2024 are estimated to be in the $417-$425 million range (exceeding previous guidance of $415 Million). Total cash holdings at the end of 2024 grew to more than $100 million.ADMA Underperfo ...

Adma Biologics (ADMA) ended the recent trading session at $16.92, demonstrating a +0.3% swing from the preceding day's closing price. The stock lagged the S&P 500's daily gain of 0.36%. Meanwhile, the Dow experienced a drop of 0.28%, and the technology-dominated Nasdaq saw an increase of 0.51%.Coming into today, shares of the infectious disease drug developer had lost 9.11% in the past month. In that same time, the Medical sector gained 5.92%, while the S&P 500 gained 2.11%.Investors will be eagerly watchin ...

This is my first cover of ADMA Biologics (NASDAQ: ADMA ). In the article, I will describe ADMA Biologics' business areas and my opinion on how they will affect the company's future. I will try to compare ADMA's product to the competition andI first entered investing in 2016 as an individual value investor. In 2022, I established the investment firm Libra Capital. I mostly write articles as part of my deep research into a company before I make an investment, whether long or short. For me, a ''hold'' article ...

Core Viewpoint - Adma Biologics is experiencing fluctuations in stock performance, with a recent increase in share price, but a decline over the past month, while upcoming financial results are anticipated to show significant year-over-year growth in earnings and revenue [1][2]. Group 1: Stock Performance - Adma Biologics shares closed at $16.47, reflecting a +1.92% change from the previous day, outperforming the S&P 500's gain of 0.61% [1] - Over the past month, shares have decreased by 7.18%, underperforming both the Medical sector's gain of 1.64% and the S&P 500's gain of 2.08% [1] Group 2: Financial Expectations - Analysts expect Adma Biologics to report earnings of $0.15 per share, indicating a year-over-year growth of 275% [2] - Revenue is forecasted to be $112.2 million, representing a 51.83% increase compared to the same quarter last year [2] Group 3: Analyst Projections - Recent shifts in analyst projections for Adma Biologics are important for investors, as positive changes indicate optimism regarding the company's business and profitability [3] - The Zacks Rank system, which incorporates these estimate changes, suggests a correlation between estimate adjustments and stock price performance [4] Group 4: Zacks Rank and Valuation - Adma Biologics currently holds a Zacks Rank of 3 (Hold), with a consensus EPS projection that has decreased by 11.61% in the past 30 days [5] - The company has a Forward P/E ratio of 23.59, which is higher than the industry average of 21.95, indicating it is trading at a premium [6] Group 5: Industry Context - The Medical - Biomedical and Genetics industry, to which Adma Biologics belongs, has a Zacks Industry Rank of 72, placing it in the top 29% of over 250 industries [6] - The Zacks Industry Rank assesses the strength of industry groups, with top-rated industries outperforming lower-rated ones by a factor of 2 to 1 [7]

Core Insights - ADMA Biologics, Inc. reported preliminary unaudited total revenue for FY 2024 between $417 million and $425 million, exceeding previous guidance of $415 million [1] - The company’s total cash holdings at year-end 2024 grew to over $100 million, reflecting a net cash surplus despite discharging $30 million of debt during Q4 2024 [1] - ADMA anticipates generating over $1 billion in total annual revenue prior to 2030, more than doubling the current 2025 revenue forecast [1][7] Financial Performance - FY 2025 and 2026 total revenue guidance is expected to exceed $485 million and $600 million, respectively [3][7] - FY 2025 and 2026 net income is expected to exceed $170 million and $230 million, respectively [3][7] - FY 2025 and 2026 adjusted EBITDA is expected to exceed $220 million and $300 million, respectively [3][7] Business Updates - Newly executed long-term high-titer plasma supply contracts are expected to support ASCENIV revenue growth through the late 2030s [2][7] - A Prior Approval Supplement (PAS) has been submitted to the FDA for an innovative yield enhancement production process, with potential regulatory approval anticipated by mid-2025 [2][7] - The innovative process is expected to increase Immunoglobulin (IG) yields by approximately 20%, driving revenue and earnings increases starting later in 2025 [2][7] Strategic Positioning - ADMA has solidified high-titer plasma supply on a long-term basis, increasing access to raw material plasma from approximately 250 collection centers, a five-fold increase in total collection capacity [7] - The company is focused on optimizing its balance sheet, having generated approximately $45 million in operating cash flow in Q4 2024, leading to a net cash surplus relative to its outstanding debt [7] - ADMA is leveraging its robust intellectual property estate and innovative R&D engine, with potential upside from its lead R&D pipeline program, SG-001, targeting S. pneumonia [7]

Core Viewpoint - ADMA Biologics has experienced a significant stock price increase of 275.7% over the past year, contrasting with a 14.3% decline in the industry, driven by strong quarterly performance and raised guidance [1][3]. Company Performance - ADMA Biologics specializes in plasma-derived biologics for treating immune deficiencies and preventing certain infectious diseases, with three FDA-approved products: Bivigam, Asceniv, and Nabi-HB [4]. - The lead product, Asceniv, is a plasma-derived IVIG that contains polyclonal antibodies, indicated for treating primary immunodeficiency disease (PIDD) in adults and adolescents [5]. Financial Highlights - Total revenues in the third quarter increased by 78%, attributed to higher sales of Asceniv and third-party plasma sales from ADMA's BioCenters [6]. - ADMA has raised its revenue guidance for 2024 to over $415 million and for 2025 to over $465 million, with net income projections exceeding $120 million in 2024 and $165 million in 2025 [9]. Product Development - ADMA is conducting a pediatric study for Asceniv, which may lead to label expansion to include pediatric patients, with a potential application filing expected in the coming quarters [7][8]. Margin and Valuation - The higher-margin product portfolio now constitutes over 50% of total revenues, with plans to increase Asceniv's supply, potentially enhancing margins and earnings growth [10]. - ADMA's shares currently trade at a price/sales ratio of 8.86x forward sales, significantly higher than the industry average of 1.69x [11]. Market Outlook - The market for plasma-derived products has substantial growth potential, particularly in the underserved immune-compromised patient population [14].

Company Overview - ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases [3] - The company currently manufactures and markets three FDA-approved plasma-derived biologics: BIVIGAM, ASCENIV™, and NABI-HB, targeting immune deficiencies and prevention of certain infectious diseases [3] - ADMA operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, and also runs ADMA BioCenters, an FDA-approved source plasma collector [3] Upcoming Events - Company management will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, from January 13-16, 2025, with ADMA's presentation scheduled for January 13, 2025, at 10:30 a.m. PT [1] - A live audio webcast of the presentation will be available on the company's investor website, with an archived version accessible approximately two hours after the event [2]

Industry Overview - Innovation is expected to drive growth in the biotech industry, particularly in obesity and oncology drugs, with strong M&A activity anticipated in 2025 [1] - The overall fundamentals of the biotech sector remain robust, and investor interest is expected to return [1][16] ADMA Biologics - ADMA Biologics markets plasma-derived biologics for immune deficiencies and infectious diseases, with three FDA-approved products: Bivigam, Asceniv, and Nabi-HB [2] - The company has shown exceptional performance in 2024, with shares increasing by 292% year to date [3] - Earnings per share estimates for 2025 have risen from 64 cents to 78 cents in the last 60 days [4] - ADMA is working to increase Asceniv's supply, which is expected to significantly contribute to total revenues and margin expansion [20] Tarsus Pharmaceuticals - Tarsus Pharmaceuticals markets Xdemvy, an eye drop for Demodex blepharitis, which generated $113.7 million in sales in the first nine months of 2024 [5][22] - The company has experienced a share price increase of 168.7% in 2024, supported by positive regulatory updates and pipeline progress [7][23] - Loss per share estimates for 2025 have narrowed from $2.10 to $1.43 in the past 60 days [7] Stoke Therapeutics - Stoke Therapeutics is developing zorevunersen for Dravet syndrome, currently in phase I/IIa studies, with Breakthrough Therapy designation granted by the FDA [8][9] - The company has seen a share price increase of 120.7% year to date, with expectations for further gains in 2025 [11][26] - Loss per share estimates for 2025 have narrowed from $2.59 to $2.49 in the past 60 days [11] ChromaDex - ChromaDex markets Niagen as a leading NAD+ booster and is developing nicotinamide riboside chloride (NRC) for ataxia telangiectasia, with FDA designations granted [12][14] - The company has experienced a share price increase of 270.6% in 2024, driven by strong sales and e-commerce growth [15][28] - Earnings per share estimates for 2025 have increased from 9 cents to 12 cents in the past 60 days [15]